Skip to main content

Table 1 Significantly differentially expressed genes (10% FDR threshold).

From: Changes in skeletal muscle gene expression following clenbuterol administration

AffyID

Gene Name

Ranka

P-valueb

Change 24 hc

Change 10 Dd

Change 10 D/24 he

1424638_at

Cyclin-dependent kinase inhibitor 1A (P21)

1

3.62E-06

23.11

2.34

-9.86

1454971_x_at

TSC22 domain family, member 1

2

4.49E-06

-1.52

n/s

1.51

1417962_s_at

Growth hormone receptor

3

6.20E-06

-2.02

-1.16

1.74

1417109_at

Tubulointerstitial nephritis antigen-like

4

8.15E-06

2.36

1.40

-1.69

1439836_at

Ankyrin repeat and SOCS box-containing protein 15

5

0.0000111

-5.38

n/s

4.15

1417357_at

Emerin

6

0.0000145

5.56

n/s

-4.36

1416313_at

Myeloid/lymphoid or mixed-lineage leukaemia

7

0.0000179

-2.69

n/s

2.59

1416156_at

Vinculin

8

0.0000234

2.04

1.81

n/s

1434985_a_at

Eukaryotic translation initiation factor 4A1

9

0.0000273

1.94

1.14

-1.71

1417574_at

Chemokine ligand 12

10

0.0000281

2.77

n/s

-3.09

1458455_at

Actin-binding Rho activating protein

11

0.0000285

4.17

n/s

-4.49

1428804_at

Microfibrilar-associated protein 3-like

12f

0.0000346

n/s

2.04

2.40

1421425_a_at

Down syndrome critical region gene 1-like 1

13

0.0000361

-1.99

-1.29

1.55

1435824_at

YY1 transcription factor

14

0.0000363

1.40

1.28

-1.09

1448907_at

Thimet oligopeptidase 1

15

0.0000407

2.23

n/s

-1.94

1452707_at

RIKEN cDNA 4631423 FO2 gene

16

0.0000411

4.34

1.39

-3.12

1451372_a_at

ADP-ribosyltransferase 1

17

0.0000451

-2.11

n/s

2.09

1448279_at

Actin related protein 2/3 complex, subunit 3

18

0.0000453

2.43

1.24

-1.95

1416256_a_at

Tubulin, beta 5

19

0.0000563

2.33

1.23

-1.89

1440838_at

Unknown

20

0.0000619

-2.01

-1.18

1.70

1439616_at

Unknown

21

0.0000684

3.57

2.91

n/s

1449088_at

Fructose bisphosphatase 2

22

0.0000703

3.95

2.21

-1.78

1452843_at

Interleukin 6 signal transducer

23

0.0000733

1.61

1.33

-1.22

1460392_a_at

Enhancer of yellow 2 homolog

24

0.0000756

2.74

n/s

-2.42

1455218_at

Serine (or cysteine) preptidase inhibitor, clade A, member 1b

25

0.0000774

2.23

1.95

n/s

1422798_at

Contactin associated protein-like 2

26f

0.0000822

-2.84

-1.60

1.78

1431043_at

Kelch repeat and BTB (POZ) domain containing 5

27

0.0000929

2.36

n/s

-2.20

1427556_at

Myosin, light polypeptide kinase 2, skeletal muscle

28

0.000094

-2.26

n/s

2.37

1423396_at

Angiotensinogen

29

0.0000957

7.84

2.99

-2.62

1418571_at

Tumor necrosis factor receptor superfamily, member 12a

30

0.000104156

35.40

n/s

-15.73

1416505_at

Nuclear receptor subfamily 4, group A, member 1

31

0.000105021

-1.65

-1.16

1.43

1416328_a_at

ATPase, H+ transporting, V0 subunit E

32

0.00010965

1.76

1.56

n/s

1434303_at

Ortholog of human Ras association and pleckstrin homolog domains 1

33

0.000112542

2.60

1.60

-1.63

1438510_a_at

Histidyl-tRNA synthetase

34

0.000118695

1.46

n/s

-1.35

1418326_at

Solute carrier family 7 (cationic amino acid transporter, y+ system), member 5

35

0.000121684

13.95

6.33

-2.20

1428662_a_at

Homebox only domain

36

0.000122982

2.19

n/s

-1.98

1444232_at

Protein kinase, cGMP-dependent, type 1

37

0.000125102

-2.95

n/s

2.37

1416379_at

Pannexin 1

38

0.000125378

3.06

3.79

n/s

1449036_at

Ring finger protein 128

39

0.000144025

4.70

2.00

-2.34

1416431_at

Tubulin, beta 6

40

0.000146038

32.86

2.61

-12.59

1448484_at

S-adenosylmethionine decarboxylase 1

41

0.00015137

-3.31

-1.49

2.22

1447160_at

Unknown

42

0.00015393

1.56

1.20

-1.30

1453851_a_at

Growth arrest and DNA-damage-inducible 45 gamma

43

0.000154877

-4.28

n/s

4.90

1422557_s_at

Metallothionein 1

44

0.000164138

11.11

2.58

-4.30

1440884_s_at

Ribonucleotide reductase M2B 9TP53 inducible

45

0.000169965

-1.73

1.25

2.15

1418111_at

Bromodomain containing 4

46

0.000174896

-6.05

-2.96

2.04

1437401_at

Insulin-like growth factor 1

47f

0.000176747

2.22

n/s

-2.47

1426440_at

Dehydrogenase/reductase (SDR family) member 7

48

0.000182143

-1.79

-1.19

1.50

1424058_at

RIKEN cDNA 1190002C06 gene

49

0.000188845

2.99

1.61

-1.86

1455643_s_at

TSR 1, 20S rRNA accumulation, homolog

50f

0.000191388

2.13

n/s

-2.31

1451751_at

DNA-damage-inducible transcript 4-like

51

0.000210837

1.89

1.22

-1.54

1421466_at

Ankyrin repeat and SOCS box-containing protein 10

52

0.000224062

-3.91

n/s

2.80

1416831_at

Neuraminidase 1

53

0.000239547

1.65

n/s

-1.51

1451924_a_at

Endothelin 1

54

0.000244042

2.76

1.37

-2.02

1427400_at

Lady bird-like homeobox 1 homolog (Drosophila)

55

0.000244505

-1.82

-1.30

1.40

1425099_a_at

Aryl hydrocarbon receptor nuclear translocator-like

56

0.000246238

3.07

n/s

-3.13

  1. aRank of P-value based on analysis of variance of all expressed genes (n = 22,605)
  2. bP-value resulting from analysis of variance. Model included treatment (control, 24 h, and 10 D clenbuterol administration) as a fixed effect. False discovery rates of 5, 10, and 20% correspond to P-values of 0.0000082, 0.00025, and 0.0012, respectively.
  3. cFold change in mRNA abundance for 24 h clenbuterol treatment relative to control. A positive fold change indicates increased mRNA abundance in 24 h treatment relative to control, a negative fold change indicates decreased mRNA abundance in 24 h treatment relative to control, and n/s indicates no significant difference between 24 h treatment and control (contrast P-value > 0.05).
  4. dFold change in mRNA abundance for 10 D clenbuterol treatment relative to control. A positive fold change indicates increased mRNA abundance in 10 D treatment relative to control, a negative fold change indicates decreased mRNA abundance in 10 D treatment relative to control, and n/s indicates no significant difference between 10 D treatment and control (contrast P-value > 0.05).
  5. eFold change in mRNA abundance for 24 h clenbuterol treatment relative to 10 D clenbuterol treatment. A positive fold change indicates increased mRNA abundance in 10 D treatment relative to 24 h treatment, a negative fold change indicates decreased mRNA abundance in 10 D treatment relative to 24 h treatment, and n/s indicates no significant difference between 10 D treatment and 24 h treatment (contrast P-value > 0.05).
  6. fResiduals of four genes meeting the 10% FDR threshold showed evidence of a non-normal distribution.
Back to article page

BMC Genomics

ISSN: 1471-2164

Contact us